Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AMRX with free AI briefings, catalyst countdowns, and dilution alerts.

AMRX · Amneal Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$157.4M Cash on Hand
CF+ Cash Runway
Follow AMRX by email Get an email when AMRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AMRX, unsubscribe in one click. Privacy

📣 What AMRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CREXONT ER Parkinson Disease Phase 4 · NCT06765668 Recruiting
Albuterol Asthma Phase 3 · NCT03549897 Unknown
Voltaren Topical Gel, 1% Osteoarthritis Phase 3 · NCT02121002 Completed
Testosterone Topical Gel, 1.62% Metered Pump Primary Hypogonadism Phase 3 · NCT02110368 Completed
Test Product Asthma Phase 3 · NCT03562949 Terminated
Test - Bimatoprost 0.01% Ophthalmic Solution Glaucoma, Open-Angle Phase 3 · NCT05401357 Recruiting
Beclomethasone Dipropionate Asthma Phase 3 · NCT03562949 Terminated
Reference - LUMIGAN® (Bimatoprost 0.01%… Glaucoma, Open-Angle Phase 3 · NCT05401357 Recruiting
Phenazopyridine Hydrochloride Tables, USP 200 mg Uncomplicated Urinary Tract Infections Phase 3 · NCT01650051 Completed
Nasonex Nasal Spray, 50 mcg Seasonal Allergic Rhinitis Phase 3 · NCT02125253 Completed
Mometasone Furoate Nasal Spray, 50 mcg Seasonal Allergic Rhinitis Phase 3 · NCT02125253 Completed
Asenapine Sublingual Tablets 10 mg Schizophrenia Phase 2/3 · NCT02072954 Completed
AndroGel (testosterone gel) 1.62% Metered-Dose… Primary Hypogonadism Phase 3 · NCT02110368 Completed
LUMIGAN® (bimatoprost ophthalmic solution) 0.01% Open-angle Glaucoma Phase 1 · NCT06267274 Unknown
KSHN001126 150mg Healthy Postmenopausal Women Phase 1 · NCT06467201 Completed
Bimatoprost Ophthalmic Solution, 0.01% Open-angle Glaucoma Phase 1 · NCT06267274 Unknown

Also used in these trials (approved or third-party drugs, not AMRX's own candidates): Testosterone Cypionate, Phenazopyridine Hydrochloride, Imatinib Mesylate, Estradiol, Diclofenac Sodium Topical Gel, 1%, Methotrexate Sodium.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AMRX holds $157.4M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 7 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AMRX files for a raise →

👥 Who Owns AMRX

Insiders 36.8% Other 5%+ holders 30.8% Institutions (457 holders) 32.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
Tushar Bhikhubhai Patel
10% owner
Insider 61,341,678 17.61% 2026-08-10
Tushar Patel 5%+ holder (13D) 61,341,678 17.61% 2026-08-10
Chintu Patel
Co-CEO, Director · +185,185 options
Insider 32,523,507 9.33% 2026-08-10
Chirag Patel 5%+ holder (13D) 29,097,645 8.35% 2026-08-10
Chirag K. Patel
President & Co-CEO, Director · +185,185 options
Insider 29,044,624 8.34% 2026-08-10
BlackRock, Inc. Institution (13G, 5%+) 24,121,119 6.92% 2026-03-31
Patel Dipan 5%+ holder (13D) 16,904,263 4.85% 2025-12-31
Gautam Patel
Director · +19,824 options
Insider 1,927,595 0.55% 2026-08-10
Paul M Meister
Director · +30,837 options
Insider 832,800 0.24% 2026-05-06
Tasos Konidaris
Executive Vice President & CFO · +87,963 options
Insider 449,434 0.13% 2026-03-03
Jeffrey P. George
Director · +19,824 options
Insider 344,614 0.10% 2026-05-06
Ted C Nark
Director · +19,824 options
Insider 325,848 0.09% 2026-05-06

Share count 348,412,726 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full AMRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AMRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.